Drug Profile
KU 2285
Alternative Names: KU-2285Latest Information Update: 10 Nov 2006
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Class Antineoplastics; Nitroimidazoles; Radiosensitisers; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Nov 2006 Discontinued - Phase-I for Cancer in Japan (Injection)
- 30 Nov 1997 Phase-I clinical trials for Cancer in Japan (Injection)
- 17 Nov 1994 Preclinical development for Cancer in Japan (Unknown route)